Released Aug 6, 2018, after the close
10-Q filed Aug 6, 2018, 37 days after period end · 0001564590-18-019456
Q2 2018 · 10-Q
Revenue$1.03M$1.03M +0.1% vs Q2 2017+0.1% vs Q1 2018
Net Income-$19.65M-$19.65M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.37-$0.37 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$19,605,000N/M
Operating Cash Flowderived-$11,523,000N/M
Free Cash Flowderived-$11,801,000N/M
Margins · derived
Operating margin-1909.0%−976.2 pt vs Q2 2017
Net margin-1913.7%−973.7 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $1.03M | $1.03M | $1.03M | $329.00K |
| Net Income | -$19.65M | -$9.65M | -$8.41M | -$7.78M |
| EPS Diluted | -$0.37 | -$0.23 | -$0.29 | -$0.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR